LUT014
EGFR inhibitor‑induced acneiform lesions in metastatic colorectal cancer
Phase 2Active
Key Facts
Indication
EGFR inhibitor‑induced acneiform lesions in metastatic colorectal cancer
Phase
Phase 2
Status
Active
Company
About Lutris Pharma
Topical B‑Raf inhibitor that reduces EGFR‑inhibitor and radiation‑induced skin side effects.
View full company profileAbout Lutris Pharma
Topical B‑Raf inhibitor that reduces EGFR‑inhibitor and radiation‑induced skin side effects.
View full company profile